New Advances in Cellular Immunotherapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".
Deadline for manuscript submissions: closed (29 April 2024) | Viewed by 2847
Special Issue Editor
Interests: adoptive therapy; hemato-oncology; hematopoietic stem cells and solid organ transplantation; graft versus host disease; genetic editing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
From the end of the nineteenth century to the modern day, immunology has produced new discoveries, showing us how powerful the immune cell response can be for treating severe diseases. Transplantation cell biology development is changing the field and improving transplantation outcomes, even overcoming classical axioms of immunology. The era of immunotherapy has focused not only on effector cells, such as T cells or natural killer (NK) cells, but also on antibody producers’ cells such as B lymphocytes, major antigen-presenting cells such as dendritic cells (DCs), and immune regulatory cell response such as mesenchymal stem cells (MSCs), hematopoietic progenitors, or myeloid-derived suppressor cells (MDSCs). Clinical studies with adoptive cell therapies and basic cell research continuously stimulate each other in a bidirectional manner. Since its initial implementation in cancer therapy, chimeric antigen receptor (CAR) expressed on immune cells has shown incredible regression rates in uncurable hematological malignancies. Unfortunately, until now, solid tumor cells and tumor cell microenvironments remain great challenges. In this Special Issue of Cells, I am glad to invite authors to submit original research articles, reviews, and prospective articles discussing recent advances in cellular immunotherapy in infants, pediatric, adolescents, young adults, and adults, proposing new strategies to overcome the current challenges in these promising therapies.
Dr. Antonio Pérez Martínez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adoptive cell therapy
- immunotherapy
- transplantation
- immune evasions
- tumor microenvironment
- genetic editing
- CAR T
- TRUCK
- NK
